10x Genomics sued Element Biosciences, alleging Element’s Aviti24 multiomic analysis platform infringes spatial technology patents licensed from Harvard University. The complaint was filed in US District Court for the District of Delaware and seeks damages, attorneys’ fees, and a permanent injunction. 10x named multiple asserted patents covering analyte detection methods and selective amplicon sequencing, according to the complaint excerpt. Element denied the allegations as meritless, arguing the lawsuit reflects a broader strategy of using the same patent portfolio to restrict innovation in spatial biology. Element said it will vigorously defend its technology and cited plans to launch direct in-tissue spatial sequencing products for fresh-frozen and FFPE tissues on the Aviti24 platform. For the spatial genomics ecosystem, patent fights can materially affect platform roadmaps, customer adoption timelines, and partnership deals.